VEGF-A121 assay
US9459263B2 · kind B2 · utility
0Cited by
0References
17Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 28, 2015 |
| Grant date | Oct 4, 2016 |
| Priority date | — |
| Expiry date | Jul 28, 2035 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/52
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The invention provides a method for enriching the level of VEGF-A121 isoform in a sample by selectively removing the VEGF-A165 isoform from the sample using a neuropilin-1 pull-down procedure, then determining the total amount of VEGF-A remaining afterward. The invention provides methods of treating a patient suffering from a disease which may benefit from the administration of a VEGF antagonist by determining the level or ratio of VEGF-A121 in the patient's circulation. Methods of diagnosis, prognosis, monitoring, and patient stratification are also provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.